Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes' army.

Autor:	García-Muñoz R; Department of Hematology, San Pedro Hospital, 26006 Logroño, La Rioja, Spain., Nájera MJ; Department of Hematology, San Pedro Hospital, 26006 Logroño, La Rioja, Spain., Feliu J; Department of Hematology, San Pedro Hospital, 26006 Logroño, La Rioja, Spain., Antón-Remírez J; Department of Physical Medicine & Rehabilitation, Navarra Hospital Complex, Pamplona, Spain., Ramalle-Gómara E; Department of Epidemiology, La Rioja Regional Authority, Logroño, La Rioja, Spain., Marín-Gorricho R; Department of Pharmacy, San Pedro Hospital, Logroño, La Rioja, Spain., Peralta R; Department of Hematology, San Pedro Hospital, 26006 Logroño, La Rioja, Spain., Gutiérrez-Gamarra E; Department of Hematology, Poniente Hospital, Almería, Andalucía, Spain., Nuñez-Rodriguez J; Department of Pharmacy, San Pedro Hospital, Logroño, La Rioja, Spain., Zafra-Morales R; Department of Pharmacy, San Pedro Hospital, Logroño, La Rioja, Spain., Aguinaga L; Department of Hematology, Centre Hospitalier Universitaire (CHU), Bordeaux, France., Nebot-Villacampa MJ; Department of Pharmacy, San Pedro Hospital, Logroño, La Rioja, Spain., Hernandez-Pérez PM; Department of Hematology, San Pedro Hospital, 26006 Logroño, La Rioja, Spain., Farfán-Quiroga G; Department of Hematology, San Pedro Hospital, 26006 Logroño, La Rioja, Spain., Panizo C; Hematology Department, University Clinic of Navarra, Pamplona, Navarra, Spain. Lymphoproliferative Group, Navarran Institute for Health Research (IDISNA), Pamplona, Navarra, Spain., Domínguez-Garrido E; Molecular Diagnostic Unit, Rioja Health Foundation, Logroño, La Rioja, Spain.
Jazyk:	angličtina
Zdroj:	Future science OA [Future Sci OA] 2019 Nov 26; Vol. 5 (10), pp. FSO425. Date of Electronic Publication: 2019 Nov 26.
DOI:	10.2144/fsoa-2019-0064
Abstrakt:	Aim: To analyze the effects of subcutaneous or intravenous rituximab + lymphokine-activated killer cells, obinutuzumab or ibrutinib on natural killer (NK) cell levels in chronic lymphocytic leukemia and follicular lymphoma patients. Patients & Methods: The distribution of peripheral blood NK cells of 31 patients was analyzed by flow cytometry. Results: We detected a decrease of NK cells in peripheral blood below normal range after obinutuzumab treatment. During maintenance treatment with subcutaneous rituximab, an NK cell reduction was less pronounced than after intravenous rituximab treatment, despite lymphokine-activated killer cell infusions. Conclusion: After one dose of obinutuzumab, each NK cell in peripheral blood destroys 25 leukemic cells. Competing Interests: Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript. (© 2019 Ricardo Garcia-Munoz.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu